Amphastar Pharmaceuticals AMPH Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's operating lease liabilities (total)?
- Amphastar Pharmaceuticals (AMPH) reported operating lease liabilities (total) of $74.91M in Q1 2026.
- What is the long-term trend for Amphastar Pharmaceuticals's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's operating lease liabilities (total) has grown at a 17.0% compound annual growth rate (CAGR), from $20.82M to $45.61M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.